Semaglutide, tirzepatide, and retatrutide represent three generations of obesity medications. Here’s how GLP-1, dual-agonist, and triple-agonist therapies compare for weight loss, metabolism, and future obesity treatment.
Retatrutide may become the next major breakthrough in obesity medicine. Here’s how the investigational triple-agonist compares with Wegovy, Mounjaro, and other GLP-1 medications for weight loss and metabolic health.
Trulicity, Ozempic, Mounjaro, Wegovy, and other GLP-1 medications are changing the treatment of obesity and type 2 diabetes. This evidence-based comparison explains the differences in weight loss results, A1C reduction, cardiovascular protection, side effects, dosing schedules, and cost to help patients understand which GLP-1 medication may fit their health goals best.
Type 2 diabetes treatment has changed rapidly in the past few years, largely because of GLP-1 receptor agonists. These medications do more than lower blood sugar. They also affect appetite, digestion, cardiovascular risk, and body weight. Two of the most widely discussed options are Trulicity and Ozempic. Both are once-weekly injectable medications approved for adults … Read more
As tirzepatide and semaglutide drive larger weight-loss results, questions about muscle preservation and body composition are becoming increasingly important in obesity medicine.
A major clinical trial found that tirzepatide produced greater average weight loss than semaglutide over 72 weeks. Here’s what researchers believe explains the difference between these two leading obesity medications.
New clinical trial data show that Zepbound users lost significantly more weight than Wegovy users over 72 weeks. Here’s how tirzepatide and semaglutide compare in effectiveness, side effects, cardiovascular benefits, and obesity treatment outcomes.
This guide explains how GLP-1 drugs work, their benefits, side effects, and safety considerations for diabetes and weight management in the U.S. and Canada.
Are Ozempic and thyroid cancer linked? Research shows no direct connection between semaglutide (Ozempic) and thyroid cancer in humans, despite concerns from rodent studies. Learn about the benefits, risks, and safety tips for those considering GLP-1 medications like Ozempic for Type 2 diabetes or weight loss.